Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative
US-11492352-B2 · Nov 8, 2022 · US
Substituted pyridotriazine compounds and uses thereof
US11897892B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11897892-B2 |
| Application number | US-202318164317-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2023 |
| Priority date | Jan 19, 2021 |
| Publication date | Feb 13, 2024 |
| Grant date | Feb 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
First claim
Opening claim text (preview).
What is claimed: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is: 4. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein the compound is: 6. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , wherein the compound is: 8. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 9. The compound of claim 1 , wherein the compound is: 10. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 , wherein the compound is: 12. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 13. The compound of claim 1 , wherein the compound is: 14. The compound of claim 1 wherein the compound is: or a pharmaceutically acceptable salt thereof. 15. The compound of claim 1 , wherein the compound is: 16. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 17. The compound of claim 1 , wherein the compound is: 18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or a pharmaceutically acceptable salt thereof. 20. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 21. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 22. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 23. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 24. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 25. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 26. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition comprises the compound: or the pharmaceutically acceptable salt thereof. 27. A method of treating an HIV infection in a human having or at risk of having the infection, comprising administering to the human a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 28. The method of claim 27 , comprising administering to the human a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 29. The method of claim 27 , comprising administering to the human a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 30. The method of claim 27 , comprising administering to the human a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 31. The method of claim 27 , comprising administering to the human a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof. 32. The method of claim 27 , comprising administering to the human a therapeutically effective amount of the compound: or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07D487/18Primary
Bridged systems · CPC title
for HIV · CPC title
in which the condensed system contains four or more hetero rings · CPC title
in which the condensed system contains four or more hetero rings · CPC title
- C07D471/18Primary
Bridged systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11897892B2 cover?
- The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).